

Santiago Bonanad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6410612/publications.pdf>

Version: 2024-02-01

79
papers

1,759
citations

394421

19
h-index

302126

39
g-index

83
all docs

83
docs citations

83
times ranked

2290
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebral calcium embolism. <i>Clinical Case Reports</i> (discontinued), 2022, 10, e04962.	0.5	0
2	ABO group-based strategy for inventory management of methylene blue-treated thawed plasma in a blood bank. <i>Transfusion and Apheresis Science</i> , 2022, , 103438.	1.0	0
3	Feasibility, safety and muscle activity during flywheel vs traditional strength training in adult patients with severe haemophilia. <i>Haemophilia</i> , 2021, 27, e102-e109.	2.1	3
4	Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEADUS system. <i>Haemophilia</i> , 2021, 27, 479-487.	2.1	8
5	Effects of a non-pharmacological approach for chronic pain management in patients with haemophilia: efficacy of cognitive-behavioural therapy associated with physiotherapy. <i>Haemophilia</i> , 2021, 27, e357-e367.	2.1	9
6	Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients. <i>Thrombosis Research</i> , 2021, 205, 99-105.	1.7	4
7	Type 2N VWD: Conclusions from the Spanish PCMVWES project. <i>Haemophilia</i> , 2021, 27, 1007-1021.	2.1	0
8	The factor VIII treatment history of non-severe hemophilia A: COMMENT. Joint damage in adult patients with mild or moderate hemophilia A evaluated with the HEADUS system. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2638-2641.	3.8	7
9	Electromyographic and Safety Comparisons of Common Lower Limb Rehabilitation Exercises for People With Hemophilia. <i>Physical Therapy</i> , 2020, 100, 116-126.	2.4	9
10	Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. <i>Clinical Pharmacokinetics</i> , 2020, 59, 245-256.	3.5	18
11	Signal transducer and activator of transcription 3 (STAT3) phosphorylation regulates thromboxane A ₂ receptor activity in human platelets. <i>British Journal of Haematology</i> , 2020, 188, e39-e42.	2.5	1
12	Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain. <i>BMJ Case Reports</i> , 2020, 13, e234142.	0.5	4
13	Adherence to prophylaxis in adult patients with severe haemophilia A. <i>Haemophilia</i> , 2020, 26, 800-808.	2.1	2
14	Increase of Neutrophil Activation Markers in Venous Thrombosis—Contribution of Circulating Activated Protein C. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5651.	4.1	24
15	Safety and Effectiveness of Progressive Moderate-to-Vigorous Intensity Elastic Resistance Training on Physical Function and Pain in People With Hemophilia. <i>Physical Therapy</i> , 2020, 100, 1632-1644.	2.4	24
16	Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort. <i>Thrombosis and Haemostasis</i> , 2020, 120, 437-448.	3.4	2
17	Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 686-688.	2.1	4
18	Next generation sequencing in bleeding disorders: two novel variants in the F5 gene (Valencia-1 and Tj ETQq000rgBT/Overlock 10 Tf 48, 674-678.	2.1	2

#	ARTICLE	IF	CITATIONS
19	Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Probands with Protein C Deficiency. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1409-1418.	3.4	8
20	Clinical and molecular characterization by next generation sequencing of Spanish patients affected by congenital deficiencies of fibrinogen. <i>Thrombosis Research</i> , 2019, 180, 115-117.	1.7	8
21	Physical Activity Monitoring and Acceptance of a Commercial Activity Tracker in Adult Patients with Haemophilia. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3851.	2.6	16
22	Upper-Body Exercises With External Resistance Are Well Tolerated and Enhance Muscle Activity in People With Hemophilia. <i>Physical Therapy</i> , 2019, 99, 411-419.	2.4	11
23	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 528-541.	2.3	18
24	Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019, 46, 427-438.	1.8	8
25	Assessment of Kinect V2 for elbow range of motion estimation in people with haemophilia using an angle correction model. <i>Haemophilia</i> , 2019, 25, e165-e173.	2.1	6
26	Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose formulated recombinant factor VIII (Kogenate [®]) and BAY 81-8973 (Kovaltry [®]) in patients with severe or moderate haemophilia A in prophylaxis. <i>Haemophilia</i> , 2019, 25, e215-e218.	2.1	9
27	Predictive factors of immune tolerance treatment response in severe haemophilia A patients with inhibitors: A real world report from a single centre, mixed retrospective-prospective long term study. <i>Haemophilia</i> , 2019, 25, e97-e100.	2.1	1
28	Joint status in Spanish haemophilia B patients assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score. <i>Haemophilia</i> , 2019, 25, 144-153.	2.1	11
29	Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A. <i>Thrombosis Research</i> , 2019, 174, 151-162.	1.7	27
30	Unraveling the effect of silent, intronic and missense mutations on <i>VWF</i> splicing: contribution of next generation sequencing in the study of mRNA. <i>Haematologica</i> , 2019, 104, 587-598.	3.5	13
31	$\hat{\pm}2$ -Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC: $\hat{\pm}2$ M Levels Are Associated with Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2018, 47, 630-638.	3.4	13
32	Moderate and severe haemophilia in Spain: An epidemiological update. <i>Haemophilia</i> , 2018, 24, e136-e139.	2.1	14
33	Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 778-790.	3.8	23
34	Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker. <i>Haemophilia</i> , 2018, 24, e28-e32.	2.1	11
35	Guía práctica de tratamiento urgente de la microangiopatía trombótica. <i>Medicina Clínica</i> , 2018, 151, 123.e1-123.e9.	0.6	7
36	Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 39-43.	3.8	39

#	ARTICLE	IF	CITATIONS
37	HemoKinect: A Microsoft Kinect V2 Based Exergaming Software to Supervise Physical Exercise of Patients with Hemophilia. <i>Sensors</i> , 2018, 18, 2439.	3.8	22
38	Practice guidelines for the emergency treatment of thrombotic microangiopathy. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 123.e1-123.e9.	0.2	2
39	Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project. <i>PLoS ONE</i> , 2018, 13, e0197876.	2.5	6
40	Pilot evaluation of home delivery programme in haemophilia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 822-828.	1.5	6
41	Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS- $\text{\textcircled{R}}$). <i>American Journal of Hematology</i> , 2017, 92, 614-621.	4.1	12
42	Further psychometric validation of the GAH scale: Responsiveness and effect size. <i>Journal of Geriatric Oncology</i> , 2017, 8, 211-215.	1.0	18
43	Effect of radiosynoviorthesis on the progression of arthropathy and haemarthrosis reduction in haemophilic patients. <i>Haemophilia</i> , 2017, 23, e497-e503.	2.1	12
44	Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients. <i>Haematologica</i> , 2017, 102, 2005-2014.	3.5	35
45	Haemo<sc>PREF</sc>: Further evaluation of patient perception and preference for treatment in a real world setting. <i>Haemophilia</i> , 2017, 23, 884-893.	2.1	7
46	Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective. <i>Haemophilia</i> , 2017, 23, 11-24.	2.1	63
47	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 837.	4.1	19
48	<sc>FVIII</sc> inhibitor development according to concentrate: data from the <sc>EUHASS</sc> registry excluding overlap with other studies. <i>Haemophilia</i> , 2016, 22, e36-8.	2.1	11
49	A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. <i>New England Journal of Medicine</i> , 2016, 374, 2054-2064.	27.0	414
50	Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. <i>Modern Pathology</i> , 2016, 29, 1541-1551.	5.5	11
51	Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2016, 34, 3284-3292.	1.6	20
52	Molecular and clinical profile of von Willebrand disease in Spain (PCM- $\text{\textcircled{E}}$ -ES): Proposal for a new diagnostic paradigm. <i>Thrombosis and Haemostasis</i> , 2016, 115, 40-50.	3.4	36
53	A simplified assay for the quantification of circulating activated protein C. <i>Clinica Chimica Acta</i> , 2016, 459, 101-104.	1.1	4
54	Platelet function in malignant hematological disorders. <i>Current Opinion in Oncology</i> , 2015, 27, 522-531.	2.4	6

#	ARTICLE	IF	CITATIONS
55	Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score. <i>Leukemia Research</i> , 2015, 39, 52-57.	0.8	18
56	Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction. <i>Leukemia Research</i> , 2015, 39, 296-306.	0.8	50
57	Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A. <i>Haemophilia</i> , 2015, 21, 458-464.	2.1	51
58	Quality of thawed plasma inactivated with methylene blue after 48-hour storage. <i>Transfusion and Apheresis Science</i> , 2015, 52, 141-142.	1.0	1
59	Home-delivered ultrasound monitoring for home treatment of haemarthrosis in haemophilia A. <i>Haemophilia</i> , 2015, 21, e147-50.	2.1	16
60	Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale. <i>Journal of Geriatric Oncology</i> , 2015, 6, 353-361.	1.0	51
61	Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A. <i>Haemophilia</i> , 2014, 20, 624-629.	2.1	10
62	Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development. <i>Haemophilia</i> , 2014, 20, 2-16.	2.1	17
63	The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. <i>Leukemia Research</i> , 2012, 36, 287-292.	0.8	22
64	Cytogenetic risk stratification in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2011, 96, 375-383.	3.5	226
65	Relationships between antithrombin activity, anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass. <i>Perfusion (United Kingdom)</i> , 2011, 26, 487-495.	1.0	16
66	P029 Prognostic relevance of specific chromosomal abnormalities in chronic myelomonocytic leukemia. <i>Leukemia Research</i> , 2009, 33, S74-S75.	0.8	0
67	P030 Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS). <i>Leukemia Research</i> , 2009, 33, S75-S76.	0.8	5
68	Low-molecular-weight heparin, bempiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study. <i>International Journal of Clinical Practice</i> , 2006, 60, 518-525.	1.7	24
69	Clotting factors in cryoprecipitate and cryo-supernatant prepared from MB-treated fresh plasma. <i>Transfusion</i> , 2000, 40, 493-493.	1.6	10
70	Influence of Methylene Blue Photoinactivation Treatment on Coagulation Factors from Fresh Frozen Plasma, Cryoprecipitates and Cryosupernatants. <i>Vox Sanguinis</i> , 2000, 79, 156-160.	1.5	43
71	Use of Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) for Carcinoembryonic Antigen, Cytokeratin 19, and Maspin in the Detection of Tumor Cells in Leukapheresis Products from Patients with Breast Cancer: Comparison with Immunocytochemistry. <i>Stem Cells and Development</i> , 1999, 8, 53-61.	1.0	34
72	A New Method for Phenotyping Red Blood Cells Using Microplates. <i>Vox Sanguinis</i> , 1999, 77, 143-148.	1.5	3

#	ARTICLE	IF	CITATIONS
73	Prolonged molecular remission after PML/RAR α -positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: is relevant pretransplant minimal residual disease in the graft?. <i>Leukemia</i> , 1998, 12, 992-995.	7.2	24
74	Comparison of Two Reverse Transcription-Polymerase Chain Reaction Methods for Detection of AML1/ETO Rearrangement in the M2 Subtype of Acute Myeloid Leukaemia. <i>Clinical Chemistry and Laboratory Medicine</i> , 1998, 36, 137-42.	2.3	1
75	Incidencia de infección por hepatitis C en donantes de cabezas femorales para el banco de tejidos. <i>Revista Espanola De Salud Publica</i> , 1998, 72, 267-271.	0.3	1
76	Minimal illegitimate levels of cytokeratin K19 expression in mononucleated blood cells detected by a reverse transcription PCR method (RT-PCR). <i>Clinica Chimica Acta</i> , 1997, 263, 105-116.	1.1	33
77	HLA-DQA, -DQB AND -DRB ALLELE CONTRIBUTION TO NARCOLEPSY SUSCEPTIBILITY. <i>International Journal of Immunogenetics</i> , 1997, 24, 409-421.	1.2	16
78	CYTOKINES AND PLATELET ACTIVATION IN STORED POOLED BUFFY COAT DERIVED PLATELET CONCENTRATES: THE ISSUE OF TRANSFUSIONAL REACTIONS. <i>British Journal of Haematology</i> , 1996, 95, 755-756.	2.5	2
79	Costs of the management of hemophilia A with inhibitors in Spain. <i>Global & Regional Health Technology Assessment</i> , 0, 8, 35-42.	0.1	1